First Patients Treated with AF Using Nano-PFA Cardiac Surgery System
Pulse Biosciences treated the first patients with atrial fibrillation (AF) using their nano-PFA cardiac surgery system in Europe, marking a significant milestone in their clinical applications.
FDA Breakthrough Device Designation
The cardiac surgery system received U.S. FDA Breakthrough Device Designation for the treatment of AF, and was enrolled in FDA's TAP program, providing even more accelerated pathways than Breakthrough.
Successful Rights Offering
The company completed their rights offering, raising $60 million in gross proceeds with the potential to raise an additional $66 million through the exercise of warrants.
Clinical Progress with Nano-PFA
Over 50 patients successfully treated with the 360 cardiac catheter, showing promise in efficiency and safety in atrial fibrillation treatments.
Financial Strengthening
As of September 30, 2024, cash and cash equivalents totaled $79 million, significantly up from $44.4 million as of December 31, 2023.